MX2022003686A - Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial. - Google Patents
Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial.Info
- Publication number
- MX2022003686A MX2022003686A MX2022003686A MX2022003686A MX2022003686A MX 2022003686 A MX2022003686 A MX 2022003686A MX 2022003686 A MX2022003686 A MX 2022003686A MX 2022003686 A MX2022003686 A MX 2022003686A MX 2022003686 A MX2022003686 A MX 2022003686A
- Authority
- MX
- Mexico
- Prior art keywords
- fgfr
- inhibitors
- immune checkpoint
- genetically altered
- patient response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Las realizaciones de la presente invención se refieren a un método de tratamiento del cáncer en un paciente que comprende la administración de un inhibidor de puntos de control inmunitarios al paciente, en donde el paciente ha sido diagnosticado de un cáncer genéticamente alterado por el FGFR, y ha sido pretratado con un inhibidor del FGFR, tal como erdafitinib.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962906517P | 2019-09-26 | 2019-09-26 | |
PCT/EP2020/076999 WO2021058798A1 (en) | 2019-09-26 | 2020-09-25 | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003686A true MX2022003686A (es) | 2022-04-25 |
Family
ID=72665262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003686A MX2022003686A (es) | 2019-09-26 | 2020-09-25 | Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220348662A1 (es) |
EP (1) | EP4034118A1 (es) |
JP (1) | JP2022550110A (es) |
KR (1) | KR20220070243A (es) |
CN (1) | CN114466662A (es) |
AU (1) | AU2020352668A1 (es) |
BR (1) | BR112022005224A2 (es) |
CA (1) | CA3151395A1 (es) |
IL (1) | IL291594A (es) |
JO (1) | JOP20220073A1 (es) |
MX (1) | MX2022003686A (es) |
WO (1) | WO2021058798A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230091944A1 (en) * | 2021-09-20 | 2023-03-23 | Droplet Biosciences, Inc. | Lymphatic fluid for diagnostics |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
KR102470456B1 (ko) | 2014-09-26 | 2022-11-23 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
EP3258966A4 (en) * | 2015-02-19 | 2018-07-25 | Bioclin Therapeutics, Inc. | Methods, compositions, and kits for treatment of cancer |
WO2017091580A1 (en) * | 2015-11-23 | 2017-06-01 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
-
2020
- 2020-09-25 US US17/763,251 patent/US20220348662A1/en active Pending
- 2020-09-25 MX MX2022003686A patent/MX2022003686A/es unknown
- 2020-09-25 JO JOP/2022/0073A patent/JOP20220073A1/ar unknown
- 2020-09-25 WO PCT/EP2020/076999 patent/WO2021058798A1/en active Application Filing
- 2020-09-25 KR KR1020227013072A patent/KR20220070243A/ko active Search and Examination
- 2020-09-25 JP JP2022519346A patent/JP2022550110A/ja active Pending
- 2020-09-25 CA CA3151395A patent/CA3151395A1/en active Pending
- 2020-09-25 BR BR112022005224A patent/BR112022005224A2/pt unknown
- 2020-09-25 CN CN202080067217.8A patent/CN114466662A/zh active Pending
- 2020-09-25 AU AU2020352668A patent/AU2020352668A1/en active Pending
- 2020-09-25 EP EP20781355.1A patent/EP4034118A1/en active Pending
-
2022
- 2022-03-22 IL IL291594A patent/IL291594A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JOP20220073A1 (ar) | 2023-01-30 |
EP4034118A1 (en) | 2022-08-03 |
WO2021058798A1 (en) | 2021-04-01 |
JP2022550110A (ja) | 2022-11-30 |
KR20220070243A (ko) | 2022-05-30 |
AU2020352668A1 (en) | 2022-03-31 |
IL291594A (en) | 2022-05-01 |
CN114466662A (zh) | 2022-05-10 |
BR112022005224A2 (pt) | 2022-06-14 |
CA3151395A1 (en) | 2021-04-01 |
US20220348662A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
AU2017382297A8 (en) | Phosphodiesterase inhibitors and methods of microbial treatment | |
AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
MX2017003227A (es) | Terapias de combinacion de inhibidores de alk. | |
EA201890968A1 (ru) | Комбинированная терапия для лечения злокачественных новообразований | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
EP4085919A3 (en) | Compositions and methods to treat cancer | |
AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
MX2017015896A (es) | Agente anticancerigeno. | |
MX2019002925A (es) | Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
EP4309738A3 (en) | Method of treating medulloblastoma with an ezh2 inhibitor | |
MX2021000847A (es) | Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077. | |
MX2019013862A (es) | Terapia de combinacion. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
PH12018502381A1 (en) | Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer | |
MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
MX2021011799A (es) | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
MX2021001870A (es) | Metodo para tratar cancer pancreatico. | |
WO2019204332A3 (en) | Pak4 inhibitors and methods of use |